Skip to main content
Premium Trial:

Request an Annual Quote

NIH, CDC to Receive Billions in Additional Funding Under Coronavirus Stimulus Bill

This story has been updated to reflect President Donald Trump's signing of the bill into law.

NEW YORK — The National Institutes of Health and the US Centers for Disease Control and Prevention will receive billions of dollars in new funding under a $2.2 trillion economic stimulus package aimed at bolstering the economy against the effects of the SARS-CoV-2 pandemic.

The spending package was approved by the US House of Representatives on Friday after clearing the US Senate earlier in the week. President Donald Trump signed it into law later on Friday.

The legislation — called the Coronavirus Aid, Relief, and Economic Security, or CARES, Act — will provide the NIH with $945.4 million in new funding. Specifically, the National Institute of Allergy and Infectious Diseases will get an additional $706 million, while the National Heart, Lung, and Blood Institute will receive an additional $103.4 million.

The National Institute of Biomedical Imaging and Bioengineering will receive an extra $60 million; the National Library of Medicine will receive an added $10 million; the National Center for Advancing Translational Sciences will get an additional $36 million; and the NIH's Office of the Director will receive an extra $30 million.

The NIH's current budget totals $41.46 billion.

The CDC, meanwhile, will receive a $4.3 billion infusion under the spending package, including $1.5 billion for grants and cooperative agreements with state and local governments.

CARES Act funding for the NIH and CDC is earmarked for preventing, preparing for, and responding to coronavirus domestically and internationally, and will be available to the agencies through Sept. 30, 2024.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.